1268 related articles for article (PubMed ID: 33059711)
1. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
2. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
Sallenave JM; Guillot L
Front Immunol; 2020; 11():1229. PubMed ID: 32574272
[TBL] [Abstract][Full Text] [Related]
3. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
4. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
Front Immunol; 2020; 11():1949. PubMed ID: 32849654
[TBL] [Abstract][Full Text] [Related]
5. Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series.
Vetter P; Eberhardt CS; Meyer B; Martinez Murillo PA; Torriani G; Pigny F; Lemeille S; Cordey S; Laubscher F; Vu DL; Calame A; Schibler M; Jacquerioz F; Blanchard-Rohner G; Siegrist CA; Kaiser L; Didierlaurent AM; Eckerle I
mSphere; 2020 Nov; 5(6):. PubMed ID: 33177214
[TBL] [Abstract][Full Text] [Related]
6. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
[TBL] [Abstract][Full Text] [Related]
7. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
[TBL] [Abstract][Full Text] [Related]
8. A global treatments for coronaviruses including COVID-19.
Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
[TBL] [Abstract][Full Text] [Related]
9. The Immune Response and Immunopathology of COVID-19.
Mortaz E; Tabarsi P; Varahram M; Folkerts G; Adcock IM
Front Immunol; 2020; 11():2037. PubMed ID: 32983152
[TBL] [Abstract][Full Text] [Related]
10. Interplay between SARS-CoV-2 and the type I interferon response.
Sa Ribero M; Jouvenet N; Dreux M; Nisole S
PLoS Pathog; 2020 Jul; 16(7):e1008737. PubMed ID: 32726355
[TBL] [Abstract][Full Text] [Related]
11. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
Quirch M; Lee J; Rehman S
J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
[TBL] [Abstract][Full Text] [Related]
12. Potential Immunotherapeutic Targets for Hypoxia Due to COVI-Flu.
Leyfman Y; Erick TK; Reddy SS; Galwankar S; Nanayakkara PWB; Di Somma S; Sharma P; Stawicki SP; Chaudry IH
Shock; 2020 Oct; 54(4):438-450. PubMed ID: 32649367
[TBL] [Abstract][Full Text] [Related]
13. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
14. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
16. Rationale for targeting complement in COVID-19.
Polycarpou A; Howard M; Farrar CA; Greenlaw R; Fanelli G; Wallis R; Klavinskis LS; Sacks S
EMBO Mol Med; 2020 Aug; 12(8):e12642. PubMed ID: 32559343
[TBL] [Abstract][Full Text] [Related]
17. COVID-19: lambda interferon against viral load and hyperinflammation.
Andreakos E; Tsiodras S
EMBO Mol Med; 2020 Jun; 12(6):e12465. PubMed ID: 32333818
[TBL] [Abstract][Full Text] [Related]
18. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.
Bhaskar S; Sinha A; Banach M; Mittoo S; Weissert R; Kass JS; Rajagopal S; Pai AR; Kutty S
Front Immunol; 2020; 11():1648. PubMed ID: 32754159
[TBL] [Abstract][Full Text] [Related]
19. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Li H; Liu Z; Ge J
J Cell Mol Med; 2020 Jun; 24(12):6558-6570. PubMed ID: 32320516
[TBL] [Abstract][Full Text] [Related]
20. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]